AR071531A1 - Compuesto cristalino heteromonociclico - Google Patents

Compuesto cristalino heteromonociclico

Info

Publication number
AR071531A1
AR071531A1 ARP090101573A ARP090101573A AR071531A1 AR 071531 A1 AR071531 A1 AR 071531A1 AR P090101573 A ARP090101573 A AR P090101573A AR P090101573 A ARP090101573 A AR P090101573A AR 071531 A1 AR071531 A1 AR 071531A1
Authority
AR
Argentina
Prior art keywords
alkyl
formula
heteromonociclic
crystal compound
group
Prior art date
Application number
ARP090101573A
Other languages
English (en)
Inventor
Takanobu Kuroita
Minoru Sasaki
Hiroki Sakamoto
Hideyuki Igawa
Tsuyoshi Maekawa
Kouhei Asano
Koji Fuji
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR071531A1 publication Critical patent/AR071531A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

Un compuesto cristalino representado por la formula (1) en donde R1 es un grupo oxo, =N-R o similares; un grupo representado por la formula (2) es un grupo representado por la formula (3), (4) o (5); R2 es un grupo representado por la formula (6); R3 y R4 son cada uno H, o alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6, alquil C1-6-amino, dialquil C1-6-amino o alquil C1-6-tio, cada uno de los cuales está opcionalmente sustituido; y R5 es H, o alquilo C1-6, alquenilo C2-6, grupo cíclico, cada uno de los cuales está opcionalmente sustituido, -CO-R8 u -O-R8'; o una de sus sales. El compuesto de la presente es de utilidad como un fármaco para la prevencion o el tratamiento de enfermedades circulatorias, enfermedades metabolicas y/o enfermedades del sistema nervioso central.
ARP090101573A 2008-05-02 2009-04-30 Compuesto cristalino heteromonociclico AR071531A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/114,048 US7803940B2 (en) 2006-11-24 2008-05-02 Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases

Publications (1)

Publication Number Publication Date
AR071531A1 true AR071531A1 (es) 2010-06-23

Family

ID=40935778

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101573A AR071531A1 (es) 2008-05-02 2009-04-30 Compuesto cristalino heteromonociclico

Country Status (7)

Country Link
US (3) US7803940B2 (es)
AR (1) AR071531A1 (es)
CL (1) CL2009001044A1 (es)
PE (1) PE20091881A1 (es)
TW (1) TW201004944A (es)
UY (1) UY31803A (es)
WO (1) WO2009133970A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056526A1 (en) * 2006-11-24 2010-03-04 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof
KR101107162B1 (ko) * 2009-12-02 2012-01-25 삼성모바일디스플레이주식회사 유기 발광 표시 장치
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
WO2012027693A2 (en) 2010-08-27 2012-03-01 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
JP2014505097A (ja) * 2011-02-08 2014-02-27 ジュビラント ライフ サイエンセズ リミテッド アジルサルタンメドキソミルの改良製造方法
GB2497806A (en) * 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
ES2663806T3 (es) 2013-12-19 2018-04-17 unshine Lake Pharma Co., Ltd. Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular
BR112016022722B8 (pt) 2014-04-01 2023-11-21 Merck Sharp & Dohme Composto, composição farmacêutica que o comprende e uso do mesmo
HUE051080T2 (hu) 2014-12-10 2021-03-01 Ono Pharmaceutical Co Dihidroindolizinon származék
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
BR112019026478A2 (pt) * 2017-06-14 2020-07-14 Trevena, Inc. compostos para modulação da atividade de s1p1 e métodos de uso dos mesmos
EP3681873A4 (en) * 2017-09-15 2021-05-26 The Regents of the University of California N-SMASE2 INHIBITION COMPOSITIONS AND METHODS
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
KR102131022B1 (ko) * 2018-07-12 2020-07-07 보령제약 주식회사 피리미디논 유도체 화합물 및 이의 용도
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena Inc COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411980A (en) 1989-07-28 1995-05-02 Merck & Co., Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
DE69013607T2 (de) 1989-08-02 1995-03-02 Takeda Chemical Industries Ltd Pyrazol-Derivate, Verfahren zu deren Herstellung und Anwendung.
EP0442473B1 (en) 1990-02-15 1998-08-19 Takeda Chemical Industries, Ltd. Pyrimidinedione derivatives, their production and use
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5166206A (en) 1990-03-30 1992-11-24 Merck & Co., Inc. Substituted pyrimidines, pyrimidinones and pyridopyrimidines
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
US5472967A (en) 1991-02-20 1995-12-05 Synthelabo 4-pyrimidinone derivatives their preparation and their application in therapy
US5164403A (en) 1991-04-05 1992-11-17 G. D. Searle & Co. N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
IT1250749B (it) 1991-08-02 1995-04-21 Luso Farmaco Inst Composti eterociclici ad attivita' a ii antagonista
CA2106135A1 (en) 1992-09-14 1994-03-15 Keiji Kubo Cyclic compounds and their use
AU4411593A (en) 1992-10-13 1994-05-09 G.D. Searle & Co. N-arylheteroarylalkyl 1-phenyl-imidazol-2-one compounds for treatment of circulatory disorders
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
CN1119861A (zh) 1993-03-24 1996-04-03 G·D·瑟尔公司 1-苯基-咪唑-2-酮联苯甲基化合物及其在治疗循环病症方面的用途
WO1995016677A1 (fr) 1993-12-16 1995-06-22 Nkk Corporation Nouveau derive de pyrimidine et composition medicinale
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
DE4431218A1 (de) 1994-09-02 1996-03-07 Bayer Ag Substituierte Pyrimidin(thi)one
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
GB0506147D0 (en) 2005-03-24 2005-05-04 Merck Sharp & Dohme Therapeutic agents
DE102005030522A1 (de) 2005-06-30 2007-01-04 Bayer Healthcare Ag Salz des Embusartans
US20100056526A1 (en) 2006-11-24 2010-03-04 Takeda Pharmaceutical Company Limited Heteromonocyclic compound and use thereof

Also Published As

Publication number Publication date
US7803940B2 (en) 2010-09-28
US20100113780A1 (en) 2010-05-06
US20100105709A1 (en) 2010-04-29
CL2009001044A1 (es) 2010-08-27
US20090176812A1 (en) 2009-07-09
PE20091881A1 (es) 2009-12-24
TW201004944A (en) 2010-02-01
US7998968B2 (en) 2011-08-16
WO2009133970A1 (en) 2009-11-05
UY31803A (es) 2009-12-14
US20110112120A9 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
AR071531A1 (es) Compuesto cristalino heteromonociclico
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
CO2017001178A2 (es) Derivado de piridona que tiene un grupo tetrahidropiranil metilo
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
CO6382126A2 (es) Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
PE20141191A1 (es) Compuestos como inhibidores de bace
AR070130A1 (es) Compuestos moduladores de beta-amiloide, un proceso para su obtencion, el uso del compuesto para la fabricacion de un medicamento y dicho medicamento
AR086474A1 (es) Compuestos de pirazol pesticidas
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR070469A1 (es) Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
CO6680700A2 (es) Compuesto heterocíclico que tiene una acción potenciadora del receptor de ampa (ácido alfa-amino-3-hidroxi-5-metil-4-isoxazolpropiónico
AR066210A1 (es) Proceso para producir compuesto amida
AR060949A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
AR082015A1 (es) Derivados de metoxifenilo heterociclicamente sustituidos con un grupo oxo, procedimientos para su preparacion y uso de los mismos como medicamentos
ECSP11010912A (es) Compuestos de pirrol
PE20091490A1 (es) Derivados sustituidos de indol
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CL2021001119A1 (es) Composición de control de organismos nocivos y método para usar la misma
ECSP11011318A (es) Derivados de benzofurano
AR083798A1 (es) Inhibidores selectivos de glucosidasas y sus usos
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure